Aligos Therapeutics
Clinical trials sponsored by Aligos Therapeutics, explained in plain language.
-
New hepatitis b pill shows promise in Head-to-Head trial
Disease control Recruiting nowThis study tests a new oral medication, ALG-000184, against an existing drug (tenofovir) for chronic hepatitis B. About 200 adults with untreated hepatitis B will take one pill daily for 48 weeks. The goal is to see if the new drug can suppress the virus better or as well as the …
Phase: PHASE2 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated May 17, 2026 12:38 UTC
-
Liver study tests hepatitis b drug safety in impaired patients
Knowledge-focused Recruiting nowThis early-stage study looks at how the body handles a single dose of the experimental hepatitis B drug pevifoscorvir sodium in people with moderate liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The …
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 12:41 UTC
-
New study checks kidney impact on hepatitis b drug
Knowledge-focused Recruiting nowThis study looks at how a single dose of the experimental drug pevifoscorvir sodium (ALG-000184) is processed by the body in people with different levels of kidney function. About 30 adults with chronic hepatitis B and either severe, mild, moderate, or normal kidney function will…
Phase: PHASE1 • Sponsor: Aligos Therapeutics • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC